Skip to content
Screener

BioMarin Pharmaceuticals BMRN Total Cost of Revenue

Total Cost of Revenue at other companies

Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$1.53M-87.7%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$3M+76.0%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$9.94M+277%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$200K
XER
Xeris Biopharma Holdings, Inc.XERS
$12.51M+5.2%
Opko Health logo
Opko HealthOPK
$83.56M-22.2%

Segments

By segment

See full
Reportable Segment$202.8M+35.1%

Other financials

Income statement

See full
Revenue$989.7M+19.9%
Gross profit$786.9M+16.5%
Operating income$110.9M-59.9%
Net income$44.8M-81.4%
EPS (diluted)$0.23-81.3%

Balance sheet

See full
Cash & equivalents$874.0M-28.0%
Total debt$4.2B+598%
Total equity$6.3B+4.9%
Total assets$11.7B+57.2%

Cash flow

See full
Operating cash flow$168.1M-9.3%
CapEx$28.8M+68.5%
Free cash flow$139.3M-17.2%

Valuation

See full
Market cap$11.58B-0.6%
Enterprise value$14.89B+34.9%
P/E32.2×-34.7×
P/S3.4×-0.4×

Profitability

See full
Gross margin76.1%-3.4pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin21.7%-1.0pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.7×+0.6×
Current ratio2.4×-3.2×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CostOfRevenue.

The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:14 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001048477-26-000016
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Royalty and other revenues5,31512,42811,44522,929
Total revenues989,708825,4101,755,9161,570,555
OPERATING EXPENSES:
Cost of sales202,795150,090397,794301,648
Research and development206,952161,308385,748320,039
Selling, general and administrative395,549232,279653,839438,395
Intangible asset amortization73,4924,84677,9759,693
Total operating expenses878,788548,5231,515,3561,069,775

Item 1. Financial Statements

FAQ

What is BioMarin Pharmaceuticals's total cost of revenue?
BioMarin Pharmaceuticals (BMRN) reported total cost of revenue of $202.8M in Q2 2026.
How has BioMarin Pharmaceuticals's total cost of revenue changed year-over-year?
BioMarin Pharmaceuticals's total cost of revenue increased by 35.1% year-over-year, from $150.09M to $202.8M.
What is the long-term trend for BioMarin Pharmaceuticals's total cost of revenue?
Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's total cost of revenue has grown at a 11.1% compound annual growth rate (CAGR), from $470.52M to $717.44M.
What does total cost of revenue mean?
The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.

Ask your AI about BioMarin Pharmaceuticals's total cost of revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude